Keith Hewitt, MD
Obstetrics & Gynecology · Bowling Green, KYNPI 1508834664
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 279 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 34 manufacturers reported payments, led by AbbVie at 26.5% of the total. Reporting peaked in 2023 at $1,101 and has fallen 68.5% since, to $347 in 2025.
Across 279 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Exeltis, USA Inc.$782
- Novo Nordisk$323
- Astellas Pharma US Inc$286
- Pfizer$246
- Hologic Sales And Service, LLC$194
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,63498%
- Education$802%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 89 | $1,249 |
| Exeltis, USA Inc. | 44 | $782 |
| Novo Nordisk | 29 | $323 |
| Astellas Pharma US Inc | 9 | $286 |
| Pfizer | 18 | $246 |
| Hologic Sales And Service, LLC | 11 | $194 |
| Organon | 9 | $183 |
| Daiichi Sankyo Inc. | 8 | $164 |
| Mayne Pharma Commercial LLC | 9 | $159 |
| Aspira Women's Health Inc | 3 | $155 |
| Channel Medsystems, Inc. | 2 | $150 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $146 |
| Biogen | 4 | $90 |
| Sumitomo Pharma America, Inc. | 3 | $46 |
| Axonics, Inc. | 3 | $46 |
| Avion Pharmaceuticals | 3 | $45 |
| Millicent US Inc | 3 | $44 |
| Duchesnay USA Incorporated | 2 | $42 |
| Baxter Healthcare | 2 | $38 |
| Amgen | 2 | $38 |
| Merck | 2 | $31 |
| Therapeuticsmd, Inc. | 2 | $29 |
| Aspen Surgical Products, Inc. | 1 | $28 |
| Roche Diagnostics Corporation | 1 | $25 |
| Meditrina | 2 | $23 |
| Johnson & Johnson | 1 | $22 |
| Caldera Medical, Inc | 1 | $21 |
| Coopersurgical, Inc. | 1 | $20 |
| Shield Therapeutics Inc | 1 | $18 |
| BD | 1 | $18 |
| Bayer | 1 | $15 |
| Lilly USA, LLC | 1 | $13 |
| Vertical Pharmaceuticals, LLC | 1 | $12 |
| Sage Therapeutics, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veozah$114
How this compares
$4,714 in reported general payments places this provider in the 85th percentile of 474 obstetrics & gynecology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 89 | $31,681 |
| MyrbetriqMirabegron | 40 | $26,838 |
| LinzessLinaclotide | 21 | $13,848 |
| GemtesaVibegron | 16 | $12,484 |
| Estradiol | 470 | $12,048 |
| PremproEstrogen,con/M-Progest Acet | 17 | $4,672 |
| Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet | 99 | $4,330 |
| ValacyclovirValacyclovir Hcl | 34 | $843 |
| FyavolvNorethindrone Ac/Eth Estradiol | 13 | $737 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 41 | $704 |
| Medroxyprogesterone Acetate | 49 | $677 |
| Clobetasol Propionate | 22 | $611 |
| Risedronate Sodium | 17 | $583 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $532 |
| Terconazole | 16 | $479 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin, Prempro | $246 | $36,352106 claims |
| Astellas Pharma US IncMyrbetriq | $286 | $26,83840 claims |
| AbbVieLinzess | $1,249 | $13,84821 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $46 | $12,48416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 474 obstetrics & gynecology providers in Kentucky.
Other obstetrics & gynecology in Bowling Green
- Nathan SticeBowling Green$199K
- Roger SandelinBowling Green$11K
- Joseph GassBowling Green$8K
- Carl DobsonBowling Green$6K
- Diana GraneseBowling Green$6K
- Andrea BrooksBowling Green$5K
- Sara MangoldBowling Green$5K
- Todd DrexelBowling Green$5K
- Devin TrevorBowling Green$5K
- Ashley HillBowling Green$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.